Risankizumab Demonstrated Superior to Apremilast for Patients With Moderate Psoriasis
Pharmacy Times,
Risankizumab (Skyrizi; AbbVie) is more effective than apremilast (Otezla; Amgen) at reducing the severity of psoriasis symptoms…
Risankizumab (Skyrizi; AbbVie) is more effective than apremilast (Otezla; Amgen) at reducing the severity of psoriasis symptoms…
Linda Stein Gold, MD Credit: Henry Ford Health In a comparison of risankizumab to apremilast among individuals with psoriasis…
Risankizumab was found to be superior to apremilast for the treatment of moderate plaque psoriasis including in patients who…
2023年8月24日 アッヴィ合同会社 スキリージ(R)(リサンキズマブ)について、中等症の尋常性乾癬成人患者さんを対象とした第IV相直接比較試験の主要評価項目においてアプレミラストに対する優越性を示したデータを発表 ー 全身療法の対象となる中等症の尋常性乾…